血清PAI-1、RBP4水平对急性ST段抬高型 心肌梗死患者PCI后无复流的预测价值.

Objective To investigate the predictive value of serum plasminogen activator inhibitor-1(PAI-1) and retinol-binding protein 4(RBP4) levels for patients with acute ST-segment elevation myocardial infarction (STEMI) with‐ out reflow after percutaneous coronary intervention (PCI). Methods Totally 129 STEMI patients were selected as the STEMI group. According to the blood flow grading of thrombolysis therapy after PCI, they were divided into the no-reflow group (38 cases) and the reflow group (91 cases), and 55 healthy subjects were selected as the control group during the same period. Clinical data of STEMI patients were collected, and serum levels of PAI-1 and RBP4 were detected by en‐ zyme-linked immunosorbent assay. The predictive value of serum PAI-1 and RBP4 levels in patients with STEMI without reflow after PCI was analyzed by receiver operating characteristic (ROC) curve. Results Compared with the control group, the serum levels of PAI-1 and RBP4 in STEMI group increased (all P<0. 05). Compared with the reflow group, the serum levels of PAI-1 and RBP4 in no-reflow group increased (all P<0. 05). Multivariate Logistic regression analysis showed that the increase of age and the increase of LDL cholesterol, PAI-1 and RBP4 were independent risk factors for noreflow after PCI in STEMI patients (all P<0. 05), and the increase of left ventricular ejection fraction was a protective fac‐ tor (P<0. 05). ROC curve analysis showed that the area under the curve of serum PAI-1 and RBP4 levels was greater than that of PAI-1 and RBP4 alone in predicting no-reflow of STEMI patients after PCI (both P<0. 05). Conclusion The in‐ creased serum levels of PAI-1 and RBP4 in STEMI patients are associated with no-reflow after PCI, and the serum PAI-1 combined with RBP4 has a high value in predicting no-reflow after PCI. [ABSTRACT FROM AUTHOR]